WO2004091521A3 - Methods and compositions for administration of trpv1 agonists - Google Patents
Methods and compositions for administration of trpv1 agonists Download PDFInfo
- Publication number
- WO2004091521A3 WO2004091521A3 PCT/US2004/011336 US2004011336W WO2004091521A3 WO 2004091521 A3 WO2004091521 A3 WO 2004091521A3 US 2004011336 W US2004011336 W US 2004011336W WO 2004091521 A3 WO2004091521 A3 WO 2004091521A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compositions
- administration
- methods
- trpv1 agonists
- capsaicin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
- A61P23/02—Local anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006509964A JP4931128B2 (en) | 2003-04-10 | 2004-04-12 | Methods and compositions for administration of TRPV1 agonists |
EP04750050.9A EP1610742B1 (en) | 2003-04-10 | 2004-04-12 | Uses and compositions for administration of capsaicin |
EA200501592A EA012599B1 (en) | 2003-04-10 | 2004-04-12 | Methods and compositions for administration of trpv1 agonists |
ES04750050.9T ES2535045T3 (en) | 2003-04-10 | 2004-04-12 | Uses and compositions for capsaicin administration |
CA2522028A CA2522028C (en) | 2003-04-10 | 2004-04-12 | Methods and compositions for administration of trpv1 agonists |
HK06107501.1A HK1085643A1 (en) | 2003-04-10 | 2006-07-03 | Uses and compositions for administration of capsaicin |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US46245703P | 2003-04-10 | 2003-04-10 | |
US46204003P | 2003-04-10 | 2003-04-10 | |
US60/462,040 | 2003-04-10 | ||
US60/462,457 | 2003-04-10 | ||
US49906203P | 2003-08-29 | 2003-08-29 | |
US60/499,062 | 2003-08-29 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2004091521A2 WO2004091521A2 (en) | 2004-10-28 |
WO2004091521A3 true WO2004091521A3 (en) | 2005-03-03 |
Family
ID=33303907
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2004/011336 WO2004091521A2 (en) | 2003-04-10 | 2004-04-12 | Methods and compositions for administration of trpv1 agonists |
Country Status (8)
Country | Link |
---|---|
US (6) | US7943166B2 (en) |
EP (2) | EP2907503A1 (en) |
JP (6) | JP4931128B2 (en) |
CA (1) | CA2522028C (en) |
EA (1) | EA012599B1 (en) |
ES (1) | ES2535045T3 (en) |
HK (2) | HK1085643A1 (en) |
WO (1) | WO2004091521A2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8952044B2 (en) | 2009-08-25 | 2015-02-10 | Pola Pharma Inc. | Antimycotic pharmaceutical composition |
Families Citing this family (72)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2907503A1 (en) | 2003-04-10 | 2015-08-19 | Neurogesx, Inc. | Methods and compositions for administration of TRPV1 agonists |
JP2006151971A (en) * | 2004-11-05 | 2006-06-15 | Maruishi Pharmaceutical Co Ltd | Insulin-like growth factor-1 secretion promoter |
WO2006066419A1 (en) * | 2004-12-22 | 2006-06-29 | Mestex Ag | Mixture of a vanilloid receptor agonist and a substance inhibiting nerve regeneration, use thereof for producing a painkiller, and method for applying said painkiller |
WO2006089012A2 (en) * | 2005-02-14 | 2006-08-24 | Neurogesx, Inc. | Device for delivery of trpv1 agonists |
WO2006105481A1 (en) * | 2005-03-30 | 2006-10-05 | Neurogesx, Inc. | Low-concentration capsaicin patch and methods for treating neuropathic pain |
GB0509573D0 (en) * | 2005-05-11 | 2005-06-15 | Merck Sharp & Dohme | Therapeutic compounds |
JP5815915B2 (en) * | 2005-10-11 | 2015-11-17 | ユニバーシティー オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケーション | Sphingomyelin liposomes for the treatment of overactive bladder disorders |
WO2007102241A1 (en) | 2006-03-08 | 2007-09-13 | Nihon Nohyaku Co., Ltd. | External pharmaceutical composition |
JP5160409B2 (en) | 2006-03-08 | 2013-03-13 | 日本農薬株式会社 | Pharmaceutical composition for external use |
US20070233211A1 (en) * | 2006-04-04 | 2007-10-04 | Galer Bradley S | Methods and compositions for treating non-neuropathic pain |
US7943666B2 (en) * | 2006-07-24 | 2011-05-17 | Trinity Laboratories, Inc. | Esters of capsaicin for treating pain |
US20080038377A1 (en) * | 2006-08-09 | 2008-02-14 | Citow Jonathan S | Device for treatment of inflamed tissue |
US20080095720A1 (en) * | 2006-10-18 | 2008-04-24 | Conopco, Inc., D/B/A Unilever | Skin Benefit Compositions with a Vanilloid Receptor Antagonist |
ES2402789T3 (en) * | 2006-11-20 | 2013-05-08 | President And Fellows Of Harvard College | Methods, compositions and kits to treat pain and pruritus |
JP5933164B2 (en) | 2007-02-06 | 2016-06-08 | ニューロクエスト インク | Composition containing terpene compound and method for inhibiting neurotransmission |
JPWO2008111296A1 (en) | 2007-03-09 | 2010-06-24 | 国立大学法人京都大学 | Pharmaceuticals for the prevention and treatment of skin diseases caused by increased keratinization |
US20080312169A1 (en) * | 2007-03-20 | 2008-12-18 | Clarence Albert Johnson | Cosmetic use of D-ribose |
US20090197819A1 (en) * | 2007-03-20 | 2009-08-06 | Clarence Albert Johnson | Compositions for improving and repairing skin |
EP2187969A2 (en) * | 2007-08-17 | 2010-05-26 | Arcion Therapeutics, Inc. | High concentration local anesthetic formulations |
CN101808638B (en) | 2007-09-05 | 2012-07-25 | 宝丽制药股份有限公司 | Antifungal composition |
HUE030028T2 (en) | 2007-09-05 | 2017-04-28 | Pola Pharma Inc | Antifungal pharmaceutical composition |
AU2008326640C1 (en) * | 2007-11-19 | 2013-07-04 | Société des Produits Nestlé S.A. | Treatment of oral pharyngeal dysphagia |
US20110086818A1 (en) * | 2008-03-11 | 2011-04-14 | Presidents And Fellows Of Harvard College | Methods, compositions, and kits for treating pain and pruritus |
US20090232750A1 (en) * | 2008-03-13 | 2009-09-17 | St Cyr John A | Compositions for indoor tanning |
US9415023B2 (en) | 2008-08-13 | 2016-08-16 | Neuroquest Inc. | Compositions comprising terpene compounds for treating negative sensory phenomena |
US8119694B2 (en) | 2008-08-15 | 2012-02-21 | Arcion Therapeutics, Inc. | High concentration local anesthetic formulations |
DK2349201T3 (en) * | 2008-10-30 | 2015-01-19 | Medlite As | Formulation for the treatment of vaginal dryness |
IL196695A (en) * | 2009-01-25 | 2015-10-29 | Secret Of Youth Ltd | Fruit and vegetable-derived compositions and uses thereof |
DE102009013469B4 (en) * | 2009-03-19 | 2014-04-17 | Bubbles And Beyond Gmbh | Preparation for external use |
JP5688405B2 (en) | 2009-04-09 | 2015-03-25 | 株式会社ポーラファルマ | Antifungal pharmaceutical composition |
KR101409792B1 (en) * | 2009-04-09 | 2014-06-19 | 니혼노야쿠가부시키가이샤 | Antimycotic pharmaceutical composition |
CA2761156C (en) * | 2009-05-07 | 2017-03-14 | University Of Cincinnati | Methods of preventing ischemic injury using peripheral nociceptive stimulation |
US20110077512A1 (en) * | 2009-06-16 | 2011-03-31 | Dept. Of Veterans Affairs | Biopsy marker composition and method of use |
CA2767646C (en) | 2009-07-10 | 2019-01-29 | President And Fellows Of Harvard College | Permanently charged sodium and calcium channel blockers as anti-inflammatory agents |
JP2012208526A (en) * | 2009-09-02 | 2012-10-25 | Sony Corp | Optical element, and display unit |
WO2011155640A1 (en) * | 2010-06-11 | 2011-12-15 | Pola Pharma Inc. | Antimycotic pharmaceutical composition |
PT2455066T (en) * | 2010-11-08 | 2018-12-06 | Epitech Group S P A | Pharmacological preparation for topical use containing n-palmitoyl-vanillamide |
US20120253143A1 (en) * | 2011-04-04 | 2012-10-04 | Raphael Warren | Method of measuring a skin agent transferred to skin |
CA2854206C (en) | 2011-09-09 | 2018-04-10 | Api Genesis, Llc | Pain relief compositions, comprising a trpv1 selective agonist, and manufacture and uses thereof |
KR101338521B1 (en) * | 2011-11-04 | 2013-12-10 | 고려대학교 산학협력단 | Rats having chronic itch or atopic dermatitis and screening method for itch and dermatitis |
US9211274B2 (en) * | 2012-02-01 | 2015-12-15 | Warsaw Orthopedic, Inc. | TRPV1 compounds in a biodegradable polymer carrier |
EP2919773A4 (en) * | 2012-11-19 | 2016-11-02 | Univ Columbia | Methods of treatment of keratinocyte-derived lesions |
US9320749B2 (en) | 2014-01-06 | 2016-04-26 | University Of Wyoming | Nanoparticle delivery system for targeted anti-obesity treatment |
MX2016013280A (en) | 2014-04-15 | 2017-04-27 | Vizuri Health Sciences Llc | Topical compositions for pain relief, manufacture and use. |
US11229600B2 (en) * | 2014-09-24 | 2022-01-25 | Vital Beverages Global Inc. | Compositions and methods for selective GI tract delivery |
CN107614061A (en) | 2014-12-01 | 2018-01-19 | 阿科莱尔斯疗法公司 | For treating the antimigraine and illness method and composition relevant with pain |
US10987328B2 (en) | 2015-02-20 | 2021-04-27 | Osmotica Kereskedelmi Es Szolgaltato Kft | Controlled release dosage form |
US10300032B2 (en) | 2015-02-20 | 2019-05-28 | Osmotica Kereskedelmi Es Szolgaltato Kft | Controlled release dosage form |
US10172800B2 (en) | 2015-02-20 | 2019-01-08 | Osmotica Kereskedelmi Es Szolgaltato Kft | Controlled release dosage form with enhanced pharmacokinetics |
US9579289B2 (en) | 2015-02-20 | 2017-02-28 | Osmotica Kereskedelmi Es Szolgaltato Kft | Controlled release dosage form |
US10898537B2 (en) * | 2015-07-31 | 2021-01-26 | Delivra Inc. | Transdermal formulations for delivery of capsaicinoids |
CN108348774A (en) | 2015-08-03 | 2018-07-31 | 哈佛大学校长及研究员协会 | Charged ion channel blocker and its application |
MX2019005202A (en) | 2016-11-02 | 2019-10-14 | Centrexion Therapeutics Corp | Stable aqueous capsaicin injectable formulations and medical uses thereof. |
AU2018302342A1 (en) | 2017-07-20 | 2020-02-06 | Centrexion Therapeutics Corporation | Methods and compositions for treatment of pain using capsaicin |
US11464858B2 (en) | 2018-06-23 | 2022-10-11 | University Of Wyoming | Magnetic nanoparticle delivery system for pain therapy |
US20200138734A1 (en) * | 2018-07-23 | 2020-05-07 | Jerry Mcshane | Topical formulation for treating bruising |
US11447444B1 (en) | 2019-01-18 | 2022-09-20 | Centrexion Therapeutics Corporation | Capsaicinoid prodrug compounds and their use in treating medical conditions |
US11254659B1 (en) | 2019-01-18 | 2022-02-22 | Centrexion Therapeutics Corporation | Capsaicinoid prodrug compounds and their use in treating medical conditions |
MA55320A (en) | 2019-03-11 | 2022-01-19 | Nocion Therapeutics Inc | ESTER SUBSTITUTED ION CHANNEL BLOCKERS AND METHODS OF USE |
MX2021010870A (en) | 2019-03-11 | 2022-01-19 | Nocion Therapeutics Inc | Charged ion channel blockers and methods for use. |
US10780083B1 (en) | 2019-03-11 | 2020-09-22 | Nocion Therapeutics, Inc. | Charged ion channel blockers and methods for use |
US10786485B1 (en) | 2019-03-11 | 2020-09-29 | Nocion Therapeutics, Inc. | Charged ion channel blockers and methods for use |
MX2021007669A (en) | 2019-03-11 | 2021-08-05 | Nippon Steel Corp | Hot-rolled steel sheet. |
EP3937945A4 (en) | 2019-03-11 | 2023-01-04 | Nocion Therapeutics, Inc. | Charged ion channel blockers and methods for use |
WO2020222187A1 (en) * | 2019-05-01 | 2020-11-05 | Clexio Biosciences Ltd. | Finished fibrous structures and methods of their use and preparation |
WO2021035037A1 (en) * | 2019-08-20 | 2021-02-25 | Georgetown University | Method to increase systemic blood pressure in shock |
WO2021091586A1 (en) | 2019-11-06 | 2021-05-14 | Nocion Therapeutics, Inc. | Charged ion channel blockers and methods for use |
BR112022008575A2 (en) | 2019-11-06 | 2022-08-09 | Nocion Therapeutics Inc | LOADED ION CHANNEL BLOCKERS AND METHODS FOR USE |
EP4118070A4 (en) | 2020-03-11 | 2024-04-10 | Nocion Therapeutics Inc | Charged ion channel blockers and methods for use |
BR112022018608A2 (en) | 2020-03-17 | 2022-11-08 | Gruenenthal Gmbh | REPEATED TOPICAL APPLICATION OF CAPSAICIN PATCH FOR THE TREATMENT OF INITIAL NON-RESPONDERS |
US20230310351A1 (en) | 2020-04-03 | 2023-10-05 | Gruenenthal Gmbh | Regimen for repeated topical application of capsaicin patch |
JP2024511973A (en) * | 2021-03-15 | 2024-03-18 | トランスポゾン セラピューティクス インコーポレイテッド | LINE-1 inhibitors for treating CNS and systemic diseases |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4892890A (en) * | 1984-11-01 | 1990-01-09 | G. D. Searle And Company | External analgesic compositions |
US5654337A (en) * | 1995-03-24 | 1997-08-05 | II William Scott Snyder | Topical formulation for local delivery of a pharmaceutically active agent |
Family Cites Families (76)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US505958A (en) * | 1893-10-03 | Register or recorder | ||
US4313958A (en) | 1980-10-24 | 1982-02-02 | The Procter & Gamble Company | Method of producing analgesia |
US4546112A (en) * | 1981-12-14 | 1985-10-08 | The Procter & Gamble Company | Method for preventing or reducing dipilatory irritation |
US4544668A (en) | 1983-07-14 | 1985-10-01 | The Procter & Gamble Company | Compounds and compositions useful for producing analgesia |
US4564633A (en) * | 1983-07-14 | 1986-01-14 | The Procter & Gamble Company | Compositions and methods useful for producing analgesia |
US4532139A (en) * | 1983-07-14 | 1985-07-30 | The Procter & Gamble Company | Compounds and compositions useful for producing analgesia |
US4544669A (en) | 1983-07-14 | 1985-10-01 | The Procter & Gamble Company | Compounds and compositions useful for producing analgesia |
US4493848A (en) | 1983-07-14 | 1985-01-15 | The Procter & Gamble Company | Compositions and methods useful for producing analgesia |
US4599342A (en) | 1984-01-16 | 1986-07-08 | The Procter & Gamble Company | Pharmaceutical products providing enhanced analgesia |
US4681897A (en) | 1984-01-16 | 1987-07-21 | The Procter & Gamble Company | Pharmaceutical products providing enhanced analgesia |
US4927687A (en) * | 1984-10-01 | 1990-05-22 | Biotek, Inc. | Sustained release transdermal drug delivery composition |
IE58110B1 (en) * | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
US4702916A (en) | 1985-12-03 | 1987-10-27 | Warner-Lambert Company | Analgesic stick compositions |
USRE37934E1 (en) * | 1986-08-28 | 2002-12-10 | Lts Lohmann Therapie-Systeme Ag | Transdermal therapeutic system |
US4863970A (en) * | 1986-11-14 | 1989-09-05 | Theratech, Inc. | Penetration enhancement with binary system of oleic acid, oleins, and oleyl alcohol with lower alcohols |
ATE113205T1 (en) | 1988-06-17 | 1994-11-15 | Procter & Gamble | APPLICATION OF VANILLIN DERIVATIVES FOR THE MANUFACTURE OF A MEDICATION FOR THE TREATMENT OF HERPES SIMPLEX INFECTION. |
US5028535A (en) * | 1989-01-10 | 1991-07-02 | Biosite Diagnostics, Inc. | Threshold ligand-receptor assay |
DK0546078T3 (en) | 1990-08-29 | 1999-09-27 | Us Health | Bird feed containing capsaicin or its derivatives or analogues |
AU9079491A (en) | 1990-11-27 | 1992-06-25 | Procter & Gamble Company, The | Combinations of vanilloid compounds and phosphonate antiviral compounds for treatment of herpes infections |
US5221692A (en) | 1991-08-22 | 1993-06-22 | National Science Council | Ether linked and relatively nonpungent analogues of N-nonanoyl vanillylamide |
US5985860A (en) * | 1992-06-03 | 1999-11-16 | Toppo; Frank | System for transdermal delivery of pain relieving substances |
CA2114968A1 (en) | 1993-02-25 | 1994-08-26 | John Wille | Transdermal treatment with mast cell degranulating agents for drug-induced hypersensitivity |
FR2722652B1 (en) * | 1994-07-22 | 1997-12-19 | Rhone Poulenc Agrochimie | FUNGICIDE COMPOSITION COMPRISING A 2-IMIDAZOLINE-5-ONE |
US5665378A (en) * | 1994-09-30 | 1997-09-09 | Davis; Roosevelt | Transdermal therapeutic formulation |
US5505958A (en) | 1994-10-31 | 1996-04-09 | Algos Pharmaceutical Corporation | Transdermal drug delivery device and method for its manufacture |
US5756107A (en) * | 1994-12-21 | 1998-05-26 | Cosmederm Technologies | Formulations and methods for reducing skin irritation |
ATE235443T1 (en) * | 1995-01-24 | 2003-04-15 | Defense Tech Corp America | TEAR GAS CONTAINING ßCAPSAICINOIDß |
US5716643A (en) * | 1995-06-07 | 1998-02-10 | Hemosphere Inc. | Large scale production of medicine coated crosslinked protein microspheres |
US5762963A (en) | 1995-06-07 | 1998-06-09 | Emory University | Method and compositions for controlling oral and pharyngeal pain using capsaicinoids |
US5882663A (en) * | 1995-10-20 | 1999-03-16 | Koeniger; Erich A. | Topical pain-relieving preparation containing C12 To C18 isoparaffins |
US6248788B1 (en) * | 1996-11-06 | 2001-06-19 | The Regents Of The University Of California | Therapeutic method with capsaicin and capasicin analogs |
US6239180B1 (en) * | 1995-11-08 | 2001-05-29 | The Regents Of The University Of California | Transdermal therapeutic device and method with capsaicin and capsaicin analogs |
CH690023A5 (en) * | 1996-02-02 | 2000-03-31 | Medichemie Ag | Local medicament for treating damage to cells of nasal mucosal, e.g. due to air pollution or smoking, contains capsaicin to improve mucociliary transport |
AUPN814496A0 (en) * | 1996-02-19 | 1996-03-14 | Monash University | Dermal penetration enhancer |
US5869533A (en) * | 1996-04-23 | 1999-02-09 | Holt; Stephen D. | Non-irritating capsaicin formulations and applicators therefor |
WO1998003641A1 (en) | 1996-07-23 | 1998-01-29 | Crandall Wilson T | Transdermal transport of molecules |
US5962532A (en) | 1997-03-13 | 1999-10-05 | Campbell; James N. | Therapeutic method with capsaicin and capsaicin analogues |
JP2002514221A (en) | 1997-05-27 | 2002-05-14 | アルゴス ファーマシューティカル コーポレーション | Analgesic composition containing capsaicinoid and enhancer thereof |
US5968539A (en) * | 1997-06-04 | 1999-10-19 | Procter & Gamble Company | Mild, rinse-off antimicrobial liquid cleansing compositions which provide residual benefit versus gram negative bacteria |
CA2294494A1 (en) | 1997-06-05 | 1998-12-10 | Richard C. K. Yen | Fibrinogen-coated microspheres |
US6013270A (en) | 1998-04-20 | 2000-01-11 | The Procter & Gamble Company | Skin care kit |
US6103266A (en) * | 1998-04-22 | 2000-08-15 | Tapolsky; Gilles H. | Pharmaceutical gel preparation applicable to mucosal surfaces and body tissues |
JP4043605B2 (en) * | 1998-07-02 | 2008-02-06 | 丸善製薬株式会社 | Method for producing capsaicin analogs |
DE69939019D1 (en) * | 1998-07-07 | 2008-08-14 | Transdermal Technologies Inc | COMPOSITIONS FOR THE RAPID AND NON-IRRITANT TRANSDERMAL ADMINISTRATION OF PHARMACEUTICALS AND METHOD FOR FORMULING THEREOF AND THEIR ADMINISTRATION |
US6946144B1 (en) * | 1998-07-08 | 2005-09-20 | Oryxe | Transdermal delivery system |
GB2340751B (en) * | 1998-08-12 | 2003-11-05 | Edko Trading Representation | Pharmaceutical compositions |
JP3211027B2 (en) * | 1998-11-13 | 2001-09-25 | 丸石製薬株式会社 | Topical containing capsaicin |
JP2000143513A (en) | 1998-11-16 | 2000-05-23 | Taisho Pharmaceut Co Ltd | Composition for external use |
US6390291B1 (en) | 1998-12-18 | 2002-05-21 | Smithkline Beecham Corporation | Method and package for storing a pressurized container containing a drug |
EP1154989B1 (en) | 1999-02-22 | 2005-12-14 | Pacific Corporation | Vanilloid analogues containing resiniferatoxin pharmacophores as potent vanilloid receptor agonists and analgesics, compositions and uses thereof |
US6294192B1 (en) | 1999-02-26 | 2001-09-25 | Lipocine, Inc. | Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents |
US6383471B1 (en) | 1999-04-06 | 2002-05-07 | Lipocine, Inc. | Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents |
US6277401B1 (en) | 1999-05-07 | 2001-08-21 | U.S. Dermatologics, Inc. | Drug delivery device |
US6299902B1 (en) * | 1999-05-19 | 2001-10-09 | The University Of Georgia Research Foundation, Inc. | Enhanced transdermal anesthesia of local anesthetic agents |
US6762158B2 (en) * | 1999-07-01 | 2004-07-13 | Johnson & Johnson Consumer Companies, Inc. | Personal care compositions comprising liquid ester mixtures |
US6348501B1 (en) * | 1999-09-29 | 2002-02-19 | Medical Merchandising, Inc. | Lotion compositions utilizing capsaicin |
JP2001114677A (en) * | 1999-10-13 | 2001-04-24 | Health Science Center:Kk | Skin coating composition |
JP2001213772A (en) * | 2000-01-28 | 2001-08-07 | Health Science Center:Kk | Skin application composition |
JP4323797B2 (en) * | 2000-07-07 | 2009-09-02 | エイ.ブイ.トップチーブ インスティテュート オブ ペトロケミカル シンセシス | Preparation of hydrophilic pressure sensitive adhesives with optimized adhesive properties |
IL137559A (en) * | 2000-07-27 | 2006-12-31 | Amnon Sintov | Transdermal drug delivery system |
US6638981B2 (en) | 2001-08-17 | 2003-10-28 | Epicept Corporation | Topical compositions and methods for treating pain |
JP2003095983A (en) * | 2001-09-21 | 2003-04-03 | Lion Corp | Skin care preparation composition |
JP2003095985A (en) * | 2001-09-26 | 2003-04-03 | Lion Corp | Blood circulation-promotive composition |
US20030104085A1 (en) | 2001-12-05 | 2003-06-05 | Yeomans David C. | Methods and compositions for treating back pain |
US6819052B2 (en) * | 2002-05-31 | 2004-11-16 | Nagano Japan Radio Co., Ltd. | Coaxial type impedance matching device and impedance detecting method for plasma generation |
LT1539124T (en) | 2002-09-05 | 2018-11-12 | Vanderbilt Royalty Sub L.P. | Compositions and kits for the removal of irritating compounds from bodily surfaces |
US20040126415A1 (en) * | 2002-11-21 | 2004-07-01 | Lu Guang Wei | Dermal delivery of a water-soluble selective cyclooxygenase-2 inhibitor |
WO2004047820A1 (en) | 2002-11-27 | 2004-06-10 | Hisamitsu Pharmaceutical Co., Inc. | Warm poultice |
MXPA05010882A (en) | 2003-04-08 | 2005-11-25 | Algorx Pharmaceuticals Inc | Preparation and purification of synthetic capsaicin. |
EP2907503A1 (en) * | 2003-04-10 | 2015-08-19 | Neurogesx, Inc. | Methods and compositions for administration of TRPV1 agonists |
BRPI0318250B8 (en) | 2003-04-14 | 2021-05-25 | Lts Lohmann Therapie Systeme Ag | topical plaster with polysiloxane matrix and method for producing a topical plaster preparation |
US20070269379A1 (en) | 2003-07-23 | 2007-11-22 | Samir Mitragotri | Penetration Enhancer Combinations for Transdermal Delivery |
PT1670433E (en) | 2003-10-10 | 2012-02-08 | Ferring Bv | Transdermal pharmaceutical formulation for minimizing skin residues |
US7244446B2 (en) * | 2003-10-16 | 2007-07-17 | Winston Laboratories, Inc. | Method for providing long-lasting pain diminishment through topical or intranasal administration of civamide |
WO2006089012A2 (en) | 2005-02-14 | 2006-08-24 | Neurogesx, Inc. | Device for delivery of trpv1 agonists |
WO2006105481A1 (en) | 2005-03-30 | 2006-10-05 | Neurogesx, Inc. | Low-concentration capsaicin patch and methods for treating neuropathic pain |
-
2004
- 2004-04-12 EP EP14198000.3A patent/EP2907503A1/en not_active Withdrawn
- 2004-04-12 US US10/823,426 patent/US7943166B2/en active Active
- 2004-04-12 CA CA2522028A patent/CA2522028C/en not_active Expired - Lifetime
- 2004-04-12 EP EP04750050.9A patent/EP1610742B1/en not_active Expired - Lifetime
- 2004-04-12 WO PCT/US2004/011336 patent/WO2004091521A2/en active Application Filing
- 2004-04-12 EA EA200501592A patent/EA012599B1/en not_active IP Right Cessation
- 2004-04-12 JP JP2006509964A patent/JP4931128B2/en not_active Expired - Lifetime
- 2004-04-12 ES ES04750050.9T patent/ES2535045T3/en not_active Expired - Lifetime
-
2006
- 2006-07-03 HK HK06107501.1A patent/HK1085643A1/en unknown
-
2010
- 2010-05-19 JP JP2010115835A patent/JP2010174046A/en not_active Withdrawn
-
2011
- 2011-04-08 US US13/083,294 patent/US8273390B2/en not_active Expired - Lifetime
- 2011-04-08 US US13/083,306 patent/US8263093B2/en not_active Expired - Lifetime
-
2012
- 2012-08-14 US US13/585,692 patent/US8734770B2/en active Active
- 2012-12-20 JP JP2012278005A patent/JP5668046B2/en not_active Expired - Lifetime
-
2014
- 2014-04-17 US US14/255,630 patent/US9750707B2/en not_active Expired - Lifetime
- 2014-08-25 JP JP2014170136A patent/JP2014240415A/en not_active Withdrawn
-
2016
- 2016-02-19 HK HK16101869.8A patent/HK1213802A1/en unknown
- 2016-10-31 JP JP2016212757A patent/JP2017019870A/en not_active Withdrawn
-
2017
- 2017-08-01 US US15/666,413 patent/US10653647B2/en not_active Expired - Lifetime
-
2018
- 2018-12-21 JP JP2018238994A patent/JP2019043962A/en not_active Withdrawn
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4892890A (en) * | 1984-11-01 | 1990-01-09 | G. D. Searle And Company | External analgesic compositions |
US5654337A (en) * | 1995-03-24 | 1997-08-05 | II William Scott Snyder | Topical formulation for local delivery of a pharmaceutically active agent |
Non-Patent Citations (1)
Title |
---|
See also references of EP1610742A4 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8952044B2 (en) | 2009-08-25 | 2015-02-10 | Pola Pharma Inc. | Antimycotic pharmaceutical composition |
Also Published As
Publication number | Publication date |
---|---|
US20110184069A1 (en) | 2011-07-28 |
JP2013060461A (en) | 2013-04-04 |
ES2535045T3 (en) | 2015-05-04 |
US7943166B2 (en) | 2011-05-17 |
JP2014240415A (en) | 2014-12-25 |
US20050090557A1 (en) | 2005-04-28 |
JP4931128B2 (en) | 2012-05-16 |
US8273390B2 (en) | 2012-09-25 |
EP1610742A2 (en) | 2006-01-04 |
JP5668046B2 (en) | 2015-02-12 |
US20120309836A1 (en) | 2012-12-06 |
US20150073056A1 (en) | 2015-03-12 |
JP2017019870A (en) | 2017-01-26 |
EP1610742B1 (en) | 2015-01-21 |
EA200501592A1 (en) | 2006-06-30 |
EA012599B1 (en) | 2009-10-30 |
WO2004091521A2 (en) | 2004-10-28 |
HK1085643A1 (en) | 2006-09-01 |
HK1213802A1 (en) | 2016-07-15 |
CA2522028A1 (en) | 2004-10-28 |
JP2006522832A (en) | 2006-10-05 |
US8734770B2 (en) | 2014-05-27 |
EP1610742A4 (en) | 2011-07-27 |
US20180169039A1 (en) | 2018-06-21 |
CA2522028C (en) | 2011-11-01 |
US9750707B2 (en) | 2017-09-05 |
US8263093B2 (en) | 2012-09-11 |
US20110196043A1 (en) | 2011-08-11 |
JP2010174046A (en) | 2010-08-12 |
US10653647B2 (en) | 2020-05-19 |
JP2019043962A (en) | 2019-03-22 |
EP2907503A1 (en) | 2015-08-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2004091521A3 (en) | Methods and compositions for administration of trpv1 agonists | |
DK1638586T3 (en) | Synergistic composition for the treatment of diabetes mellitus | |
WO2004108133A3 (en) | Modulators of vr1 receptor | |
TW200605870A (en) | Topical methadone compositions and methods for using the same | |
WO2005034998A3 (en) | Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions | |
TW200616650A (en) | Semi-solid delivery vehicle and pharmaceutical compositions | |
WO2006094263A3 (en) | Compositions and methods for topical application and transdermal delivery of botulinum toxins | |
WO2007101224A3 (en) | Inhibitors of the unfolded protein response and methods for their use | |
WO2004091540A3 (en) | Methods of treating pain and compositions for use therefor | |
HUP0303197A2 (en) | Compositions containing alpha-2 adrenergic agonist components | |
WO2004080430A3 (en) | Methods of improving skin quality | |
WO2005084410A3 (en) | Compositions and methods for topical application and transdermal delivery of botulinum toxins | |
BRPI0615819B8 (en) | process for preparing a drug delivery composition comprising an active agent and a crystalline fumaryl diketopiperazine microparticle. | |
SG156624A1 (en) | Organo-gel formulations for therapeutic applications | |
WO2005007142A3 (en) | Liquid compositions comprising formoterol | |
WO2006083979A3 (en) | Local treatment of neurofibromas | |
WO2007028022A3 (en) | Novel compounds as p2x7 modulators and uses thereof | |
WO2004045557A3 (en) | Novel lapachone compounds and methods of use thereof | |
WO2002094189A3 (en) | Compositions and methods for treating or preventing convulsions or seizures | |
WO2003066597A3 (en) | Guanidino compounds | |
WO2005107467A3 (en) | Compositions including opioids and methods of their use in treating pain | |
WO2005117913A3 (en) | Ozonized pharmaceutical composition and method | |
TWI372047B (en) | Topical pain relief compositions of n,2,3-trimethyl-2-isopropylbutamide and methods for using the same | |
WO2004087098A3 (en) | Preserved ophthalmic compositions | |
RS106704A (en) | Stabilised pharmaceutical compositions on the basis of polyoxyethylated castor oil and method for manufacturing the same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DPEN | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2006509964 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2522028 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004750050 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200501592 Country of ref document: EA |
|
WWP | Wipo information: published in national office |
Ref document number: 2004750050 Country of ref document: EP |